ZSAN - Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

Zosano Pharma's (ZSAN) Qtrypta, an intracutaneous (patch) version of Zomig (zolmitriptan), is safe and efficacious when given over the course of a year.New data, published in The Journal of Headache and Pain, found that of 5,963 migraine attacks treated over 12 months, felt pain relief at two hours post-dose in 81% of migraine attacks, pain freedom in 44% of attacks, and most bothersome symptom freedom in 62% of attacks.Zosano says its proprietary transdermal microneedle system in the patch allows zolmitriptan to more easily enter the bloodstream.Zosano shares are up 23% to $0.92 in after-hours trading.

For further details see:

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%